Hereditary Hemorrhagic Telangiectasia (HHT) Center
Can you apply?
This grant is for establishing or expanding regional Centers of Excellence for Hereditary Hemorrhagic Telangiectasia (HHT). Applicants must be accredited medical institutions, teaching hospitals, or medical research organizations with expertise in rare hematological and vascular diseases. Centers must demonstrate capacity to provide specialized clinical care, conduct research, and offer training for healthcare providers in HHT diagnosis and management.
The Centers are expected to serve regional populations and collaborate with national HHT networks. Applicants should have established patient populations, diagnostic capabilities, and research infrastructure. Funding supports multidisciplinary programs addressing clinical care, education, and research coordination.
Institutions must have institutional review board approval for research components. Previous experience managing rare diseases or participation in disease registries is advantageous. This is a competitive program requiring demonstrated commitment to HHT clinical excellence.
Key dates
- Mar 16, 2026 Applications open
- Jun 15, 2026 Application deadline in 14 days
- Aug 2, 2026 Award announced
- Sep 1, 2026 Project start
This grant is for establishing or expanding regional Centers of Excellence for Hereditary Hemorrhagic Telangiectasia (HHT). Applicants must be accredited medical institutions, teaching hospitals, or medical research organizations with expertise in rare hematological and vascular diseases. Centers must demonstrate capacity to provide specialized clinical care, conduct research, and offer training for healthcare providers in HHT diagnosis and management.
The Centers are expected to serve regional populations and collaborate with national HHT networks. Applicants should have established patient populations, diagnostic capabilities, and research infrastructure. Funding supports multidisciplinary programs addressing clinical care, education, and research coordination.
Institutions must have institutional review board approval for research components. Previous experience managing rare diseases or participation in disease registries is advantageous. This is a competitive program requiring demonstrated commitment to HHT clinical excellence.
Program description
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Who can apply
Eligible applicants
Details
This grant is for establishing or expanding regional Centers of Excellence for Hereditary Hemorrhagic Telangiectasia (HHT). Applicants must be accredited medical institutions, teaching hospitals, or medical research organizations with expertise in rare hematological and vascular diseases. Centers must demonstrate capacity to provide specialized clinical care, conduct research, and offer training for healthcare providers in HHT diagnosis and management.
The Centers are expected to serve regional populations and collaborate with national HHT networks. Applicants should have established patient populations, diagnostic capabilities, and research infrastructure. Funding supports multidisciplinary programs addressing clinical care, education, and research coordination.
Institutions must have institutional review board approval for research components. Previous experience managing rare diseases or participation in disease registries is advantageous. This is a competitive program requiring demonstrated commitment to HHT clinical excellence.
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (Federal Application for Federal Assistance)
- Project Narrative and Statement of Need
- Organizational Capacity and Experience Documentation
- Detailed Budget and Budget Narrative
- Letters of Support (partner institutions, referring physicians, patient groups)
- Curriculum Vitae for Key Personnel
- Institutional Review Board Approval or Assurance
- Evaluation Plan
Program contact
- 👤 Nordia Williams
- 📧 nwilliams1@hrsa.gov
- 📞 240-475-3310
Funding track record
Recent awards under CFDA 93.110 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$51,517,055
-
$48,495,269
-
$47,831,055
-
$37,182,998
-
$30,109,677
-
$20,269,976
-
$19,582,050
-
$16,167,482
-
$15,667,860
-
$14,859,999
Top States by Funding
- DC 8 awards $151.7M
- MA 7 awards $111.9M
- MD 8 awards $66.8M
- OH 2 awards $58.9M
- NC 3 awards $43.2M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.110). How funding has trended year over year.
| 2024 | $274,459,189 | |
| 2025 | $265,688,703 | |
| 2026 est. | $185,664,902 |
FAQ
What type of organization can apply for HHT Center funding?
Medical schools, teaching hospitals, academic medical centers, and research institutions with established hematology or vascular medicine programs can apply. Your institution should have existing patient populations with HHT or rare vascular disease expertise.
What activities does this funding support?
Funding supports clinical care delivery, diagnostic services, research programs, provider training, and patient education. Centers coordinate specialty services across multiple disciplines.
How competitive is this grant?
This is a highly competitive federal grant. Applicants need demonstrated expertise in rare diseases, established research capacity, and strong institutional commitment.
What is the typical funding range?
HHT Center grants typically provide multi-year funding ranging from several hundred thousand to over a million dollars annually, depending on scope and institutional capacity.
When should I submit my application?
Applications open March 16, 2026. Check HRSA's official portal for exact submission deadlines and any extensions announced closer to the deadline.
💡 Tips for applicants
- Emphasize your institution's existing capacity to diagnose and manage HHT. Highlight current patient volume and specialty expertise.
- Build a strong multidisciplinary team including hematologists, interventional radiologists, otolaryngologists, and genetic counselors.
- Demonstrate clear connections to national HHT patient networks and registries to show regional impact potential.
- Include letters of support from referring physicians, patient advocacy groups, and partner institutions in your region.
- Develop a detailed budget that allocates resources for clinical care, research, education, and administrative infrastructure separately.
⚠️ Common mistakes
Applicants underestimate the need for multidisciplinary team composition and don't adequately describe existing HHT patient populations. Weak or absent research components fail to demonstrate center innovation beyond clinical service delivery. Applications lacking clear regional coordination plans or partnerships with patient advocacy organizations score poorly.
Similar grants
- OPEN 2026 JAG/SCIP Innovation — Iowa Governor's Office of Drug Control Policy
- CLOSING SOON FY26 RFP PHTHOET26001 for EMS System Development and Sustainability Assessment — Iowa Department of Health and Human Services
- OPEN IOWAccess Program FY26 — Iowa Administrative Services
- OPEN SFY2027 – Emergency Medical Services Grant Program — Montana Department of Transportation
- CLOSED 2025 AGR Pulse Research & Market Development Program — Montana Department of Agriculture